[ad_1]
The “Smoothened Homolog (Protein Gx or SMO) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.
Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND /CTA Filed and Preclinical stages are 2, 4, 3, 1 and 2 respectively.
The report outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with …
Full story available on Benzinga.com
[ad_2]
Source link
